網(wǎng)站介紹 關(guān)于我們 聯(lián)系方式 廣告業(yè)務(wù) 幫助信息
1998-2022 ChinaKaoyan.com Network Studio. All Rights Reserved. 滬ICP備12018245號(hào)
分類:導(dǎo)師信息 來(lái)源:中國(guó)考研網(wǎng) 2015-03-26 相關(guān)院校:廣東醫(yī)科大學(xué)
陸元志,男, 博士,廣東醫(yī)學(xué)院海外引進(jìn)高層次專門人才, 碩士研究生導(dǎo)師(病理學(xué)與病理生理學(xué)專業(yè))。2006年畢業(yè)于北京協(xié)和醫(yī)學(xué)院/清華大學(xué)醫(yī)學(xué)部生物化學(xué)與分子生物學(xué)專業(yè),獲博士學(xué)位。2007年3月到美國(guó)俄亥俄州立大學(xué)醫(yī)學(xué)中心和腫瘤中心(The Medical Center, The Comrehensive Cancer Center,The Ohio State University)工作,任博士后研究員和高級(jí)研究員(Sr. Research Scientist)(Dr. Gustavo Leone實(shí)驗(yàn)室),2014年5月全職回國(guó)工作。現(xiàn)任湛江市醫(yī)學(xué)會(huì)病理學(xué)分會(huì)副主任委員 ,美國(guó)癌癥研究協(xié)會(huì)(AACR)會(huì)員和美國(guó)生物化學(xué)與分子生物學(xué)協(xié)會(huì)(ASBMB)會(huì)員 ; PLOS one、Journal of Experimental & Clinical Cancer Research、Development Growth and Differentiation和The Internet Journal of Oncology等國(guó)際雜志的特約審稿人。
長(zhǎng)期從事分子腫瘤學(xué)和分子病理學(xué)研究、教學(xué)和臨床病理診斷工作,參與完成多項(xiàng)美國(guó)NIH P01、R01、R21研究項(xiàng)目 、國(guó)家“863”高新技術(shù)項(xiàng)目以及國(guó)家自然科學(xué)基金面上和重點(diǎn)項(xiàng)目等一系列前沿研究課題,主要研究細(xì)胞周期調(diào)控異常與B細(xì)胞淋巴瘤的發(fā)生發(fā)展和乳腺癌微環(huán)境在乳腺癌發(fā)生、耐藥、轉(zhuǎn)移中的作用。發(fā)表研究論文20篇,多次參加美國(guó)癌癥研究協(xié)會(huì)(AACR)和美國(guó)乳腺癌協(xié)會(huì)舉辦的國(guó)際性會(huì)議并進(jìn)行論文交流。研究成果的主要學(xué)術(shù)貢獻(xiàn)有:(1)首次發(fā)現(xiàn)了細(xì)胞周期G1期調(diào)控因子CDK4的缺失會(huì)促進(jìn)B 細(xì)胞淋巴瘤的發(fā)生發(fā)展,提示靶向CDK4的治療可能存在一定的危險(xiǎn)(The Journal of clinical investigation,JCI);(2)發(fā)現(xiàn)抑制microRNA-222和-181b對(duì)逆轉(zhuǎn)乳腺癌他莫昔芬耐藥有一定的幫助(JBC);(3)發(fā)現(xiàn)了Hedgehog信號(hào)通路是他莫昔芬(Tamoxifen)耐藥的一條關(guān)鍵信號(hào)通路并受異常激活的PI3K/AKT信號(hào)通路調(diào)控,靶向這兩條信號(hào)通路可能有助于克服乳腺癌他莫昔芬的耐藥(Cancer Research)。目前承擔(dān)國(guó)家自然科學(xué)基金面上項(xiàng)目一項(xiàng)(No. 81372298)。主要研究領(lǐng)域:(1)分子腫瘤學(xué):主要通過(guò)現(xiàn)代分子/細(xì)胞生物學(xué)技術(shù)、動(dòng)物模型機(jī)臨床相關(guān)研究探討癌細(xì)胞與微環(huán)境共進(jìn)化分子機(jī)制、腫瘤轉(zhuǎn)移分子機(jī)制及靶向治療;(2)分子病理學(xué):主要是腫瘤分子病理診斷新技術(shù)、新靶點(diǎn)的開(kāi)發(fā)與應(yīng)用等。
近五年代表性論文:
1.Yuanzhi Lu, Yongsheng Wu, Xiaoling Feng, Rulong Shen, Weiqiang Zhao, Jing H. Wang, Mohammad Fallahi, Weimin Li, Chunying Yang, William Hankey, Ming O. Li, Ramesh K. Ganju, John L. Cleveland and Xianghong Zou. CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis. J Clin Invest. 2014 Apr 1, 2014; 124(4): 1672–1684. PMID:24614102.
2.Xinmei Wang a, Hongyan He a, Yuanzhi Lu b,Wei Ren c, Kun-yu Tengc, Chi-ling Chiang c,Zhaogang Yang a,Bo Yu a, Shuhao Hsub, Samson T. Jacobb,c, Kalpana Ghoshal b,c, L. James Lee a,d,. Indole-3-carbinol inhibits tumorigenicity of hepatocellular carcinoma cells via suppression of microRNA-21 and upregulation of phosphatase and tensin homolog. Biochim Biophys Acta. 2015 Jan;1853(1):244-53, PMID:2544767.
3.Shu-hao Hsu, Bo Yu, Xinmei Wang, Yuanzhi Lu, Carl R Schmidt, Robert J Lee, L James Lee, Samson T Jacob, Kalpana Ghoshal. Cationic Lipid Nanoparticles for Therapeutic Delivery of siRNA and miRNA to Murine Liver Tumor. Nanomedicine. 2013 Nov;9(8):1169-80. May 30. pii: S1549-9634(13)00192-5. doi:10.1016/j.nano.2013.05.007. [Epub ahead of print] PMID: 23727126
4.Bhuvaneswari Ramaswamy, Yuanzhi Lu#, Kun-yu Teng, Gerrard Nuovo, Xiaobai Li, Charles M. Shapiro and Sarmila Majumder. Hedgehog signaling is a novel therapeutic target in tamoxifen resistant breast cancer aberrantly activated by PI3K/AKT pathway Cancer Research, 2012 Oct 1;72(19):5048-59 PMID:22875023 ( #co-first author)
5.Yuanzhi Lu, Satavisha Roy, Tyler Miller, Kalpana Ghoshal, Bhuvaneswari Ramaswamy, Charlie Shapiro, Samson T. Jacob, Sarmila Majumder. Anti-microRNA-222 (Anti-miR-222) and -181B Suppress Growth of Tamoxifen-resistant Xenografts in Mouse by Targeting TIMP3 Protein and Modulating Mitogenic Signal. J Biol Chem. 2011 Dec 9; 286(49):42292-302. Epub 2011 Oct 18, PMID: 22009755.
6.Yuanzhi Lu, Qiao Liu, Bo Liu, Xinxin Song, Zhixin Zhang, Mingrong Huang Qingzheng Zhao. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model. Biol Pharm Bull 2007; 30(1):150-6. PMID: 17202676
聯(lián)系方式
地址:廣東省湛江市霞山區(qū)文明東路2號(hào),廣東醫(yī)學(xué)院(524923)
電話:0759-2388584(O);Email: yzhlu01@yahoo.com
掃碼關(guān)注
考研信息一網(wǎng)打盡
網(wǎng)站介紹 關(guān)于我們 聯(lián)系方式 廣告業(yè)務(wù) 幫助信息
1998-2022 ChinaKaoyan.com Network Studio. All Rights Reserved. 滬ICP備12018245號(hào)